- |||||||||| hydroxychloroquine / VG Lifesciences
Clinical, Journal: A Case of Pancytopenia with Many Possible Causes: How Do You Tell Which is the Right One? (Pubmed Central) - Apr 2, 2019
This report reiterates the importance of the differential diagnosis of pancytopenia, especially in immunosuppressed patients with increased risk for opportunistic infections. The possibility of multiple aetiologies for pancytopenia in the same patient should be considered.Azathioprine-induced myelotoxicity is dose-dependent and pancytopenia is a rare form of presentation.Opportunistic infections should always be considered as a cause of cytopenias when immunosuppression is present.
- |||||||||| prednisolone / generics, methotrexate / generics
Journal: Dermatomyositis as a paraneoplastic phenomenon in oesophageal cancer. (Pubmed Central) - Mar 28, 2019
The oesophageal adenocarcinoma was treated with a gastrointestinal endoscopic mucosal resection and subsequent oesophajectomy. The patient's dermatomyositis was treated successfully with oral prednisolone and methotrexate.
- |||||||||| prednisolone / generics
Journal: Macrophage enzyme and reduced inflammation drive brain correction of mucopolysaccharidosis IIIB by stem cell gene therapy. (Pubmed Central) - Mar 27, 2019
...As the disease is characterized by increased inflammation, we also tested the anti-inflammatory steroidal agent prednisolone alone, or in combination with LV.NAGLU, to understand the importance of inflammation on behaviour...This was attributed to a decrease in peripheral inflammatory cytokines. Here we show significant neurological disease correction is achieved using haematopoietic stem cell gene therapy, suggesting this therapy alone or in combination with anti-inflammatories may improve neurological function in patients.
- |||||||||| methylprednisolone / generics
Clinical, Journal: Optic neuritis following diphtheria, tetanus, pertussis, and inactivated poliovirus combined vaccination: a case report. (Pubmed Central) - Mar 27, 2019
Although the association between immunizations and the onset of central nervous system demyelinating conditions is well documented, this report, to the best of our knowledge, is the first case of optic neuritis following diphtheria, tetanus, pertussis, and inactivated poliovirus combined vaccination. Inclusion of this case report in the medical community will allow for broader understanding of possible conditions that may present shortly after receipt of vaccination.
- |||||||||| prednisolone / generics
Biomarker, Journal: Chronic Glucocorticoid Exposure Induces Depression-Like Phenotype in Rhesus Macaque (Macaca Mulatta). (Pubmed Central) - Mar 26, 2019
...Seven male macaques were selected and randomized to glucocorticoid or vehicle groups, which were subjected to either prednisolone acetate or saline injections, respectively...This could be possibly explained by lower dopamine (DA) levels in cerebrospinal fluid induced by chronic glucocorticoid treatment. The results presented here indicate that chronic glucocorticoid exposure could disturb both the acute and chronic HPA axis reactivity, which eventually disturbed the neurotransmitter system and led monkeys to display depression-like phenotype.
- |||||||||| prednisolone / generics
Preclinical, Journal, IO Biomarker: Fangchinoline Promotes Autophagy and Inhibits Apoptosis in Osteoporotic Rats. (Pubmed Central) - Mar 25, 2019
Histopathology revealed that the apoptosis of osteoblasts was decreased in the fangchinoline-treated group compared to the prednisolone group of rats. CONCLUSIONS Fangchinoline inhibits apoptosis of osteoblasts and protects against bone loss in prednisolone-induced osteoporosis rats by inducing autophagy.
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical, Review, Journal: Management of adults with Burkitt lymphoma. (Pubmed Central) - Mar 22, 2019
The infusional regimen of dose-adjusted etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin, and regular- or double-dose rituximab (DA-EPOCH-R or -RR) is less toxic than standard BL regimens, yet maintains high rates of cure across a diverse range of patients, including those with disseminated disease, advanced age, and HIV infection...Still, patients with CNS involvement remain at high risk for early death, and prevention of late CNS relapses remains a priority. Future studies combining rational targeted agents with DA-EPOCH-R or -RR may further improve the cure rate.
- |||||||||| prednisolone / Generic mfg., prednisone / Generic mfg., methotrexate / Generic mfg.
Enrollment open: CHASM-CS-RCT: Cardiac Sarcoidosis Randomized Trial (clinicaltrials.gov) - Mar 22, 2019
P3, N=194, Recruiting,
Future studies combining rational targeted agents with DA-EPOCH-R or -RR may further improve the cure rate. Not yet recruiting --> Recruiting
- |||||||||| Neupogen (filgrastim) / Kyowa Kirin, Amgen, Neulasta (pegfilgrastim) / Roche, Matulane (procarbazine hydrochloride) / Leadiant Biosci
Trial completion date, Trial primary completion date, FDG PET, Metastases: RATHL: Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma (clinicaltrials.gov) - Feb 12, 2019
P3, N=1202, Active, not recruiting,
Not yet recruiting --> Recruiting Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Dec 2018 --> Jun 2019
- |||||||||| Remicade (infliximab) / J&J
Enrollment closed: Top-down Infliximab Study in Kids With Crohn's Disease (clinicaltrials.gov) - Feb 8, 2019
P4, N=100, Active, not recruiting,
Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Dec 2018 --> Jun 2019 Enrolling by invitation --> Active, not recruiting
- |||||||||| NN1213 / Novo Nordisk
Trial completion, Trial completion date, Trial primary completion date: Cortico-cop: Corticosteroid Reduction in COPD (clinicaltrials.gov) - Feb 8, 2019
P4, N=318, Completed,
Enrolling by invitation --> Active, not recruiting Recruiting --> Completed | Trial completion date: Aug 2019 --> Jan 2019 | Trial primary completion date: Dec 2018 --> Sep 2018
- |||||||||| prednisolone / Generic mfg., mycophenolate mofetil / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: Astronef: Absence of Steroid in Renal Transplantation and Digital Fibrosis Observation (clinicaltrials.gov) - Jan 31, 2019
P4, N=193, Completed,
Recruiting --> Completed | Trial completion date: Aug 2019 --> Jan 2019 | Trial primary completion date: Dec 2018 --> Sep 2018 Active, not recruiting --> Completed | Trial completion date: Oct 2016 --> Aug 2018 | Trial primary completion date: Oct 2016 --> Aug 2018
- |||||||||| JNJ-1887 / J&J
Enrollment change: AAVCAGsCD59 for the Treatment of Wet AMD (clinicaltrials.gov) - Jan 8, 2019
P1, N=25, Recruiting,
Active, not recruiting --> Completed | Trial completion date: Oct 2016 --> Aug 2018 | Trial primary completion date: Oct 2016 --> Aug 2018 N=10 --> 25
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical, P2 data, Clinical Trial,Phase I, Clinical Trial,Phase II, Journal: Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. (Pubmed Central) - Jan 1, 2019
P2
N=10 --> 25 In this study, DA-EPOCH-R produced durable remission in patients with MYC-rearranged aggressive B-cell lymphomas and should be considered for the treatment of these diseases.
- |||||||||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
New P3 trial, BRCA Biomarker, PARP Biomarker: Study of Olaparib (Lynparza (clinicaltrials.gov) - Dec 21, 2018
P3, N=340, Not yet recruiting,
- |||||||||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
Enrollment closed, BRCA Biomarker, PARP Biomarker: Study of Olaparib (Lynparza (clinicaltrials.gov) - Dec 21, 2018
P3, N=340, Active, not recruiting,
In this study, DA-EPOCH-R produced durable remission in patients with MYC-rearranged aggressive B-cell lymphomas and should be considered for the treatment of these diseases. Recruiting --> Active, not recruiting
- |||||||||| clobetasol propionate topical / Generic mfg.
New trial: Intradermal LPS and Antibiotics (clinicaltrials.gov) - Dec 19, 2018
P=N/A, N=30, Recruiting,
- |||||||||| Trial primary completion date: DETECT: Descemet Endothelial Thickness Comparison Trial (clinicaltrials.gov) - Dec 5, 2018
P4, N=50, Active, not recruiting,
Recruiting --> Completed | N=120 --> 5 | Trial primary completion date: Mar 2019 --> Nov 2018 Trial primary completion date: Oct 2018 --> Apr 2018
- |||||||||| prednisolone / Generic mfg., prednisone / Generic mfg., methotrexate / Generic mfg.
Trial initiation date: CHASM-CS-RCT: Cardiac Sarcoidosis Randomized Trial (clinicaltrials.gov) - Oct 11, 2018
P3, N=194, Not yet recruiting,
Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020 Initiation date: Sep 2018 --> Dec 2018
- |||||||||| JNJ-1887 / J&J
Enrollment open: AAVCAGsCD59 for the Treatment of Wet AMD (clinicaltrials.gov) - Sep 14, 2018
P1, N=10, Recruiting,
Trial completion date: Sep 2017 --> Sep 2019 | Trial primary completion date: Sep 2017 --> Sep 2019 Not yet recruiting --> Recruiting
- |||||||||| prednisolone / Generic mfg.
Trial completion, Trial completion date, Trial initiation date: A Study Evaluating Vitamin D in Allergic Bronchopulmonary Aspergillosis Complicating Asthma (clinicaltrials.gov) - Aug 23, 2018
P2/3, N=30, Completed,
Trial completion date: Jun 2017 --> Dec 2018 | Trial primary completion date: Jun 2017 --> Dec 2018 Not yet recruiting --> Completed | Trial completion date: Dec 2018 --> Jun 2018 | Initiation date: May 2017 --> Dec 2016
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical, P2 data, Journal: R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study. (Pubmed Central) - Aug 16, 2018
P2
However, most discontinuations occurred during maintenance therapy, suggesting that rituximab over a 4-year span is not feasible for many patients. Nonetheless, this sequential therapeutic strategy resulted in good overall outcomes for patients, including a low incidence of early disease progression.
- |||||||||| Review, Journal, IO biomarker: Advances in Diagnosis and Management of Diffuse Large B-cell Lymphoma. (Pubmed Central) - Jul 11, 2018
We also discuss the front-line management of primary mediastinal large cell lymphoma using the EPOCH (etoposide, prednisolone, Oncovin [vincristine], cyclophosphamide, hydroxydaunorubicin [doxorubicin]) regimen and examine new salvage data on immune checkpoint inhibitors for this clinical subtype...The most popular salvage regimens and the application of high-dose chemotherapy with stem cell transplantation are assessed in detail. Finally, data on new treatment tactics such as CART (chimeric antigen receptor T-cell) cells and promising new drugs, including blinatumomab and venetoclax, are presented.
- |||||||||| prednisolone / Generic mfg., cyclophosphamide / Generic mfg.
Enrollment open, Phase classification, Trial completion date, Trial primary completion date: Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of ESRD (clinicaltrials.gov) - Jun 20, 2018
P2/3, N=56, Recruiting,
Finally, data on new treatment tactics such as CART (chimeric antigen receptor T-cell) cells and promising new drugs, including blinatumomab and venetoclax, are presented. Not yet recruiting --> Recruiting | Phase classification: PN/A --> P2/3 | Trial completion date: May 2021 --> Aug 2021 | Trial primary completion date: Mar 2021 --> Aug 2021
|
